N
Nadia Chouaki
Researcher at Eli Lilly and Company
Publications - 35
Citations - 2014
Nadia Chouaki is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Pemetrexed & Maintenance therapy. The author has an hindex of 15, co-authored 35 publications receiving 1798 citations.
Papers
More filters
Journal ArticleDOI
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,E. Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: There was a significant reduction in the risk of disease progression over the placebo group, and the primary endpoint was progression-free survival in the intention-to-treat population.
Journal ArticleDOI
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Mike Thomas,Jean-Louis Pujol,Paolo Bidoli,Olivier Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: Pemetrexed continuation maintenance therapy is well-tolerated and offers superior OS compared with placebo, further demonstrating that it is an efficacious treatment strategy for patients with advanced nonsquamous NSCLC and good performance status who did not progress during pemetrexing-cisplatin induction therapy.
Journal ArticleDOI
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
Suresh Senan,Anthony Brade,Lu Hua Wang,Johan Vansteenkiste,Shaker R. Dakhil,Bonne Biesma,Maite Martinez Aguillo,Joachim G.J.V. Aerts,Ramaswamy Govindan,Belén Rubio-Viqueira,Conrad R. Lewanski,David R. Gandara,Hak Choy,Tony Mok,Anwar Hossain,Neill Iscoe,Joseph Treat,Andrew Koustenis,Belen San Antonio,Nadia Chouaki,Everett E. Vokes +20 more
TL;DR: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexe was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.
Journal ArticleDOI
Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis
Jean-Louis Pujol,Sofia Paul,Nadia Chouaki,Patrick Peterson,Patti Moore,Donald A. Berry,Marc Salzberg +6 more
TL;DR: An analysis of survival without grade 3/4 toxicity suggests a benefit-to-risk profile that favors pemetrexed over docetaxel in the second-line treatment of patients with non-small cell lung cancer.
Journal ArticleDOI
PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
Luis Paz-Ares,Filippo de Marinis,Mircea Dediu,Michael Thomas,Jean-Louis Pujol,Paolo Bidoli,Oliver Molinier,Tarini Prasad Sahoo,Eckart Laack,Martin Reck,Jesus Corral Jaime,Symantha Melemed,William J. John,Nadia Chouaki,Annamaria Zimmermann,Carla Visseren-Grul,Cesare Gridelli +16 more
TL;DR: The PARAMOUNT trial showed that pem continuation maintenance therapy significantly reduced the risk of disease progression over plb (HR=0.62; 95% CI: 0.49-0.79; p <0.0001) in patients (pts) with advanced NS NSCLC who had not progressed during pem-cis induction as mentioned in this paper.